公开(公告)号：EP1833800A1

公开(公告)日：2007-09-19

申请号：EP05855204.3

申请日：2005-12-22

申请人： AstraZeneca AB ,  NPS PHARMACEUTICALS, INC.

发明人： BALESTRA, Michael, c/o AstraZeneca Wilmington ,  BUNTING, Heather, c/o AstraZeneca Wilmington ,  CHEN, Deborah, c/o GlaxoSmithKline N&GI CEDD ,  EGLE, Ian ,  FORST, Janet, AstraZeneca Wilmington ,  FREY, Jennifer ,  ISAAC, Methvin ,  MA, Fupeng ,  NUGIEL, David, c/o AstraZeneca Wilmington ,  SLASSI, Abdelmalik ,  STEELMAN, Gary, c/o AstraZeneca Wilmington ,  SUN, Guang-ri ,  SUNDAR, Babu, c/o AstraZeneca Wilmington ,  UKKIRAMAPANDIAN, Radhakrishnan ,  URBANEK, Rebecca A., c/o AstraZeneca Wilmigton ,  WALSH, Sally, c/o AstraZeneca Wilmington

IPC分类号： C07D231/22 ,  C07D231/20 ,  A61P25/28

CPC分类号： C07D401/14 ,  C07D211/62 ,  C07D231/22 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D413/14 ,  C07D417/12 ,  C07D471/08 ,  C07D471/10 ,  C07D491/10

摘要： Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.